傑瑞股份(002353.SZ):德石股份創業板IPO申請被深交所中止審核
格隆匯8月19日丨傑瑞股份(002353.SZ)公佈,此前披露,分拆控股子公司德石股份至創業板上市獲深交所審核通過。因德石股份為本次發行聘請的律師事務所因其為其他公司提供的法律服務而被中國證監會立案調查,目前尚未最終結案。根據《深圳證券交易所創業板股票發行上市審核規則》第六十四條的相關規定,深圳證券交易所於2021年8月18日中止德石股份發行上市審核。
德石股份與中介機構將嚴格按照相關法律以及深圳證券交易所的要求,完成恢復審核所需的各項準備工作,並儘快提交恢復審核申請。公司將持續關注德石股份首次公開發行股票後續進展情況,並根據相關法律、法規要求及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.